Exact Sciences Corporation
Exact Sciences is dedicated to eradicating cancer by helping to prevent it, detect it earlier, and guide personalized treatment. With a global presence, they focus on innovation, health equity, and collaborations to improve health outcomes and make a meaningful difference in communities worldwide.
Industries
Nr. of Employees
Very Large (1000+)
Exact Sciences Corporation
5505 Endeavor Lane, Madison, WI 53719
Patents
Products
At‑home stool DNA colorectal screening test
Prescription‑based at‑home stool collection test that analyzes DNA markers and fecal blood to screen average‑risk adults for colorectal cancer.
Tumor genomic profiling panel for therapy selection
Comprehensive DNA‑ and RNA‑based genomic test that provides a molecular profile of a patient’s tumor to support treatment decisions.
Multi‑cancer early detection (MCED) blood test
Blood‑based assay under development/clinical deployment intended to detect signals from multiple cancer types at early stages.
Hereditary cancer risk test (blood or saliva)
Germline genetic testing using blood or saliva samples to provide gene‑specific and familial cancer risk reporting.
At‑home stool DNA colorectal screening test
Prescription‑based at‑home stool collection test that analyzes DNA markers and fecal blood to screen average‑risk adults for colorectal cancer.
Tumor genomic profiling panel for therapy selection
Comprehensive DNA‑ and RNA‑based genomic test that provides a molecular profile of a patient’s tumor to support treatment decisions.
Multi‑cancer early detection (MCED) blood test
Blood‑based assay under development/clinical deployment intended to detect signals from multiple cancer types at early stages.
Hereditary cancer risk test (blood or saliva)
Germline genetic testing using blood or saliva samples to provide gene‑specific and familial cancer risk reporting.
Services
Provision of accredited laboratory testing services for cancer screening, hereditary risk, and tumor profiling.
Partnerships with academic and clinical research institutions to co‑develop biomarkers, license technologies, and run joint studies.
Operational and educational support for community screening initiatives, including culturally tailored materials, on‑site engagement, and grant funding programs.
Dedicated medical affairs contacts and customer support channels for providers and laboratories to address clinical and operational questions.
Provision of accredited laboratory testing services for cancer screening, hereditary risk, and tumor profiling.
Partnerships with academic and clinical research institutions to co‑develop biomarkers, license technologies, and run joint studies.
Operational and educational support for community screening initiatives, including culturally tailored materials, on‑site engagement, and grant funding programs.
Dedicated medical affairs contacts and customer support channels for providers and laboratories to address clinical and operational questions.
Expertise Areas
- Clinical trial management and validation
- Molecular diagnostics
- Next‑generation sequencing and bioinformatics
- Biomarker discovery and assay development
Key Technologies
- Stool DNA testing
- Cell‑free DNA sequencing (cfDNA)
- DNA methylation analysis
- RNA/DNA tumor profiling
News & Updates
Validation of the next-generation Cologuard test showing high cancer sensitivity and specificity.
FDA lowers screening age for Cologuard to 45
The FDA updates guidelines to include adults aged 45 and older for colorectal cancer screening.
Introduction of Riskguard hereditary cancer test
A new test providing gene-specific and familial risks for 10 common cancers.
College students discover how their work can help break down barriers to good health outcomes.
Using mathematical models and real-world data to guide cancer research and decision-making.
Supporting cancer patients through advocacy, community engagement, and education.
Validation of the next-generation Cologuard test showing high cancer sensitivity and specificity.
FDA lowers screening age for Cologuard to 45
The FDA updates guidelines to include adults aged 45 and older for colorectal cancer screening.
Introduction of Riskguard hereditary cancer test
A new test providing gene-specific and familial risks for 10 common cancers.
College students discover how their work can help break down barriers to good health outcomes.
Using mathematical models and real-world data to guide cancer research and decision-making.
Supporting cancer patients through advocacy, community engagement, and education.